Joshua Makower - 28 Jun 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: 10%+ Owner
Signature: /s/ Sasha Keough, attorney-in-fact
Issuer symbol: GLUE
Transactions as of: 28 Jun 2021
Transactions value $: $19,950,000
Form type: 4
Filing time: 30 Jun 2021, 18:06:19
Previous filing: 24 Jun 2021
Next filing: 29 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GLUE	Common Stock	Conversion of derivative security		+2.72M			2.72M	28 Jun 2021	See Note 2	F1, F2
transaction	GLUE	Common Stock	Conversion of derivative security		+3.26M	+119.93%		5.97M	28 Jun 2021	See Note 2	F1, F2
transaction	GLUE	Common Stock	Conversion of derivative security		+669K	+11.2%		6.64M	28 Jun 2021	See Note 2	F1, F2
transaction	GLUE	Common Stock	Purchase	$20M	+1.05M	+15.81%	$19.00	7.69M	28 Jun 2021	See Note 2	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	GLUE	Series A-2 convertible preferred stock	Conversion of derivative security	-9.59M	-100%	28 Jun 2021	Common Stock	2.72M	See Note 2	F1, F2
transaction	GLUE	Series B convertible preferred stock	Conversion of derivative security	-11.5M	-100%	28 Jun 2021	Common Stock	3.26M	See Note 2	F1, F2
transaction	GLUE	Series C convertible preferred Stock	Conversion of derivative security	-2.36M	-100%	28 Jun 2021	Common Stock	669K	See Note 2	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2	The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Content

Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a one-for-3.5305 basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.

The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.